Редактирование: CYP2B6

Cytochrome P450 2B6 (EC 1.14.13.-) (1,4-cineole 2-exo-monooxygenase) (CYPIIB6) (Cytochrome P450 IIB1)

==Publications==

{{medline-entry
|title=Developmental Expression of [[CYP2B6]]: A Comprehensive Analysis of mRNA Expression, Protein Content and Bupropion Hydroxylase Activity and the Impact of Genetic Variation.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/26608082
|abstract=Although [[CYP2B6]] catalyzes the biotransformation of many drugs used clinically for children and adults, information regarding the effects of development on [[CYP2B6]] expression and activity are scarce. Utilizing a large panel of human liver samples (201 donors: 24 fetal, 141 pediatric, and 36 adult), we quantified [[CYP2B6]] mRNA and protein expression levels, characterized [[CYP2B6]] (bupropion hydroxylase) activity in human liver microsomes (HLMs), and performed an extensive genotype analysis to differentiate [[CYP2B6]] haplotypes such that the impact of genetic variation on these parameters could be assessed. Fetal livers contained extremely low levels of [[CYP2B6]] mRNA relative to postnatal samples and fetal HLMs did not appear to catalyze bupropion hydroxylation; however, fetal [[CYP2B6]] protein levels were not significantly different from postnatal levels. Considerable interindividual variation in [[CYP2B6]] mRNA expression, protein levels, and activity was observed in postnatal HLMs (mRNA, ∼40,000-fold; protein, ∼300-fold; activity, ∼600-fold). The extremely wide range of interindividual variability in [[CYP2B6]] expression and activity was significantly associated with age (P < 0.01) following log transformation of the data. Our data suggest that [[CYP2B6]] activity appears as early as the first day of life, increases through infancy, and by 1 year of age, [[CYP2B6]] levels and activity may approach those of adults. Surprisingly, [[CYP2B6]] interindividual variability was not significantly associated with genetic variation in [[CYP2B6]], nor was it associated with differences in gender or ethnicity, suggesting that factors other than these are largely responsible for the wide range of variability in [[CYP2B6]] expression and activity observed among a large group of individuals/samples.
|mesh-terms=* Adolescent
* Adult
* Age Factors
* Aged
* Aging
* Biotransformation
* Bupropion
* Child
* Child, Preschool
* Cytochrome P-450 CYP2B6
* Female
* Gene Expression Regulation, Developmental
* Gene Expression Regulation, Enzymologic
* Gene Frequency
* Gestational Age
* Haplotypes
* Humans
* Hydroxylation
* Infant
* Infant, Newborn
* Liver
* Male
* Microsomes, Liver
* Middle Aged
* Pharmacogenetics
* Pharmacogenomic Variants
* RNA, Messenger
* Substrate Specificity
* Young Adult

|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4931886
}}
{{medline-entry
|title=Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/16368442
|abstract=Major depressive disorder (MDD) is a common psychiatric condition, with 6.6% of the adult population in the United States experiencing a major depressive episode during any given year. Depressed patients must receive adequate treatment to maximize the likelihood of clinical success. Bupropion hydrochloride, a noradrenergic/dopaminergic antidepressant, is available in 3 oral formulations: immediate release (IR) (given TID), sustained release (SR) (given BID), and extended release (XL) (given QD). Understanding the pharmacokinetic (PK) properties and formulations of bupropion can help optimize clinical use. : The aims of this article were to provide a review of the PK properties of bupropion and identify its various formulations and clinical applications to help optimize treatment of MDD. : In this review, data concerning PK trials/reports were collected from articles identified using a PubMed search. The search was conducted without date limitations and using the search terms bupropion, bupropion SR, bupropion XL, bupropion pharmacokinetics, bupropion metabolism, and bupropion drug interactions. Additional reports were selected from references that appeared in articles identified in the original search. In addition, data from studies summarized in product information and labeling were obtained. All available information, concentrating on studies in humans, pertinent to bupropion PK properties and/or formulations was included. : Bupropion is extensively metabolized by the liver (t(1/2), approximately 21 hours). Hydroxybupropion, the primary active metabolite (t(1/2), approximately 20 hours), is formed by cytochrome P450 (CYP) 2B6. At steady state, C(max) of hydroxybupropion is 4- to 7-fold higher, and the AUC is approximately 10-fold greater, compared with those of the parent drug. Threohydrobupropion and erythrohydrobupropion (mean [SD] t(1/2) values, approximately 37 [13] and approximately 33 [10] hours, respectively), the other active metabolites of bupropion, are formed via nonmicrosomal pathways. Relative to bupropion, the C(max) values are approximately 5-fold greater for threohydrobupropion and similar for erythrohydrobupropion. Based on a mouse antitetrabenazine model, hydroxybupropion is approximately 50% as active as bupropion, and threohydrobupropion and erythrohydrobupropion are approximately 20% as active as bupropion. Bupropion lowers the seizure threshold and, therefore, concurrent administration with other agents that lower the seizure threshold should be undertaken cautiously. Potential interactions with other agents that are metabolized by [[CYP2B6]] should be considered. In addition, bupropion inhibits [[CYP2D6]] and may reduce clearance of agents metabolized by this enzyme. Absorption of the XL formulation is prolonged compared with the IR and SR formulations (T(max), approximately 5 hours vs approximately 1.5 and approximately 3 hours, respectively). Bupropion is dosed without regard to food. : Understanding the PK profile and formulations of bupropion can help optimize clinical use. Bupropion is metabolized extensively, resulting in 3 active metabolites. This metabolic profile, various patient factors (eg, age, medical illnesses), and potential drug interactions should be considered when prescribing bupropion. The 3 formulations-bupropion, bupropion SR, and bupropion XL-are bioequivalent and offer options to optimize treatment for patients with MDD.
|mesh-terms=* Aging
* Animals
* Antidepressive Agents, Second-Generation
* Area Under Curve
* Aryl Hydrocarbon Hydroxylases
* Bupropion
* Cytochrome P-450 CYP2B6
* Delayed-Action Preparations
* Depressive Disorder, Major
* Drug Interactions
* Half-Life
* Humans
* Liver Failure
* Metabolic Clearance Rate
* Oxidoreductases, N-Demethylating
* Polymorphism, Genetic
* Renal Insufficiency
* Sex Factors
* Smoking

|full-text-url=https://sci-hub.do/10.1016/j.clinthera.2005.11.011
}}
{{medline-entry
|title=Cytochrome P450 3A and 2B6 in the developing kidney: implications for ifosfamide nephrotoxicity.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/15875221
|abstract=Repeated administration of agents (e.g., cancer chemotherapy) that can cause drug-induced nephrotoxicity may lead to acute or chronic renal damage. This will adversely affect the health and well-being of children, especially when the developing kidney is exposed to toxic agents that may lead to acute glomerular, tubular or combined toxicity. We have previously shown that the cancer chemotherapeutic ifosfamide (IF) causes serious renal damage substantially more in younger children (less than 3 years of age) than among older children. The mechanism of the age-related IF-induced renal damage is not known. Our major hypothesis is that renal CYP P450 expression and activity are responsible for IF metabolism to the nephrotoxic chloroacetaldehyde. Presently, the ontogeny of these catalytic enzymes in the kidney is sparsely known. The presence of [[CYP3A4]], 3A5 and 2B6 was investigated in human fetal, pediatric and adult kidney as was the metabolism of IF (both R-IF and S-IF enantiomers) by renal microsomes to 2-dechloroethylifosfamide (2-DCEIF) and 3-dechloroethylifosfamide (3-DCEIF). Our analysis shows that CYP 3A4 and 3A5 are present as early as 8 weeks of gestation. IF is metabolized in the kidney to its two enantiomers. This metabolism can be inhibited with CYP 3A4/5 and 2B6 specific monoclonal inhibitory antibodies, whereby the [[CYP3A4]]/5 inhibitory antibody decreased the production of R-3-DCEIF by 51%, while the inhibitory [[CYP2B6]] antibody decreased the production of S-2-DCEIF and S-3-DCEIF by 44 and 43%, respectively, in patient samples. Total renal CYP content is approximately six-fold lower than in the liver.
|mesh-terms=* Adolescent
* Adult
* Aged
* Aged, 80 and over
* Aging
* Antibodies, Monoclonal
* Antineoplastic Agents, Alkylating
* Aryl Hydrocarbon Hydroxylases
* Blotting, Western
* Child
* Child, Preschool
* Cyclophosphamide
* Cytochrome P-450 CYP2B6
* Cytochrome P-450 CYP3A
* Fetus
* Humans
* Ifosfamide
* Immunohistochemistry
* Infant
* Kidney
* Microsomes
* Middle Aged
* Oxidoreductases, N-Demethylating
* Stereoisomerism

|full-text-url=https://sci-hub.do/10.1007/s00467-004-1807-3
}}
{{medline-entry
|title=The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/15364537
|abstract=We have measured cytochrome P450 (CYP) activity in nearly 150 samples of human liver microsomes and 64 samples of cryopreserved human hepatocytes, and we have performed induction studies in over 90 preparations of cultured human hepatocytes. We have analyzed these data to examine whether the expression of CYP enzyme activity in liver microsomes and isolated hepatocytes or the inducibility of CYP enzymes in cultured hepatocytes is influenced by the gender, age, or ethnicity of the donor (the latter being limited to Caucasians, African Americans, and Hispanics due to a paucity of livers from Asian donors). In human liver microsomes, there were no statistically significant differences (P > 0.05) in CYP activity as a function of age, gender, or ethnicity with one exception. 7-Ethoxyresorufin O-dealkylase ([[CYP1A2]]) activity was greater in males than females, which is consistent with clinical observation. Liver microsomal testosterone 6beta-hydroxylase ([[CYP3A4]]) activity was slightly greater in females than males, but the difference was not significant. However, in cryopreserved human hepatocytes, the gender difference in [[CYP3A4]] activity (females = twice males) did reach statistical significance, which supports the clinical observation that females metabolize certain [[CYP3A4]] substrates faster than do males. Compared with those from Caucasians and African Americans, liver microsomes from Hispanics had about twice the average activity of [[CYP2A6]], [[CYP2B6]], and [[CYP2C8]] and half the activity of [[CYP1A2]], although this apparent ethnic difference may be a consequence of the relatively low number of Hispanic donors. Primary cultures of hepatocytes were treated with beta-naphthoflavone, an inducer of [[CYP1A2]], phenobarbital or rifampin, both of which induce [[CYP2B6]], [[CYP2C9]], [[CYP2C19]], and [[CYP3A4]], albeit it to different extents. Induction of these CYP enzymes in freshly cultured hepatocytes did not appear to be influenced by the gender or age of the donor. Furthermore, [[CYP3A4]] induction in hepatocytes isolated from cirrhotic liver was comparable to that in normal hepatocytes, which supports the "healthy hepatocyte, sick environment" hypothesis of liver cirrhosis. This review summarizes these findings and discusses their implications for the use of human liver microsomes and hepatocytes for in vitro studies of drug metabolism and enzyme induction, which play a key role in drug development.
|mesh-terms=* Aging
* Alcohol Drinking
* Animals
* Cells, Cultured
* Cytochrome P-450 Enzyme System
* Enzyme Induction
* Ethnic Groups
* Female
* Hepatocytes
* Humans
* Isoenzymes
* Liver Cirrhosis
* Male
* Microsomes, Liver
* Sex Characteristics
* Smoking

|full-text-url=https://sci-hub.do/10.1016/j.taap.2004.01.010
}}